Silicone scar treatment preparation

1. A spreadable preparation for aiding in wound healing and improving the characteristics of the post-epithelialially developed tissue at a wound site, the preparation comprising:

a) a volatile component;

b) siloxane matrix precursors capable of forming a siloxane matrix at temperatures in the range of from about 95 to 100 degrees Fahrenheit during evaporation of the volatile component and comprising an amount ranging from 25 wt % to 60 wt % of the overall spreadable preparation;

c) an active component having low miscibility and low solubility in the siloxane matrix precursors; and

d) a volatile coagent, the volatile coagent including at least one selected from the group consisting of dimethyl isosorbide, isopropyl myristate, pentylene glycol, and isopropyl myristate;

wherein:

the volatile coagent being capable of forming a complex with the active component to form a solubilized active component;

the complex being miscible in said siloxane matrix precursors;

the active component being mobile within a siloxane matrix such that the active component can move to the wound site;

the active component being a steroid compound in an amount ranging from 0.5 wt % to 3.0 wt % of the overall composition or an agent having sun screening activity, the agent having sun screening activity comprising octinoxate (ISP escalol 557) and octisalate (ISP escalol 587); and

at least a portion of the volatile coagent evaporates from the preparation upon the formation of the siloxane matrix.

2. The spreadable preparation of claim 1 , wherein the volatile coagent is an ester of a linear acid having a carbon chain length in the range of from about 6 to 13 carbon atoms and methanol, ethanol, or a secondary alcohol having a total carbon content in the range of from about 3 to about 8 carbon atoms.

3. The spreadable preparation of claim 1 , wherein the volatile coagent is a glycol comprised of a linear chain of three or more carbons and one or more hydroxyl group, and wherein said one or more hydroxyl group being on adjacent carbons, an end carbon, or an adjacent carbon and an end carbon.

4. The spreadable preparation of claim 1 , wherein the active component comprises an agent having antihistamine or pain relieving activity.

5. The spreadable preparation of claim 1 , wherein the agent having sun screening activity further comprises at least one or more selected from the group consisting of octocrylene (ISP escalol 597) and oxybenzone (ISP escalol 567).

6. The spreadable preparation of claim 1 , wherein the steroid compound is hydrocortisone acetate USP.

7. The spreadable preparation of claim 1 , wherein the siloxane matrix precursors comprise dimethicone crosspolymer, fumed silica, and dimethicone.

8. The spreadable preparation of claim 1 , wherein the volatile component is a cyclic siloxane being present in the preparation at a concentration ranging from 12 wt % to 45 wt % of the overall preparation.

9. The spreadable preparation of claim 8 , wherein the volatile component is cyclopentasiloxane.

10. A method for preparing the spreadable preparation of claim 1 , the method comprising:

combining (i) the volatile component, (ii) the siloxane matrix precursors, (iii) the active component, and (iv) the volatile coagent to form a mixture;

wherein:

the siloxane matrix precursors are capable of forming a siloxane matrix at temperatures in the range of from about 95 to 100 degrees Fahrenheit during evaporation of the volatile component when the siloxane matrix precursors and the volatile component are combined;

the volatile coagent includes at least one selected from the group consisting of dimethyl isosorbide, isopropyl myristate, pentylene glycol, and isopropyl myristate, and the volatile coagent is capable of forming a complex with the active component to form a solubilized active component being miscible in said siloxane matrix precursors and mobile within the siloxane matrix such that said active component may move through the preparation to a wound site; and

at least a portion of said volatile coagent evaporates from the preparation upon the formation of the siloxane matrix.

11. A composition for topical application to a human subject in need thereof, the composition comprising:

a) a volatile component having a cyclic siloxane and being present in the composition at a concentration ranging from 12 wt % to 45 wt % of the overall composition;

b) siloxane matrix precursors having dimethicone and dimethicone cross polymers and ranging from 25 wt % to 60 wt % of the overall composition;

c) an active component comprising a steroid compound in an amount ranging from 0.5 wt % to 3.0 wt % of the overall composition; and

d) a glycol containing compound being present in the composition at a concentration ranging from 5 wt % to 50 wt % of the overall composition.

12. The composition of claim 11 , wherein the steroid compound is hydrocortisone acetate USP in an amount ranging from 0.5 wt % to 1.0 wt % of the overall composition.

13. The spreadable preparation of claim 1 , wherein the volatile component comprises a cyclic siloxane at a concentration ranging from 12 wt % to 45 wt % of the overall spreadable preparation.